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Abstract 
This article proposes a field study on the applications and impacts of Industry 
4.0 (I4.0) in the biopharmaceutical sector, based on an initial literature 
review. The world is facing a new industrial revolution that is happening at a 
faster pace than the previous ones. The central idea is the integration between 
the virtual and the real world through elements that will allow a greater degree 
of automation and digitization of processes The fieldwork, carried out between 
July and December 2019, considered semi-structured interviews with 
managers of pharmaceutical companies or specialists in the I4.0 theme. The 
interviews pointed out the need for the biopharmaceutical sector to adapt to 
the concepts of I4.0 and identified its main benefits and barriers. The 
perceptions were considerably diversified, with the benefits in operational 
efficiency, productivity and quality being the most scored items. Regarding the 
main barriers, the most  highlighted by the interviewees were the need to break 
organizational cultural standards, regulatory requirements, the lack of 
organizational strategies for implementation and the lack of qualified 
professionals. In conclusion, this work in progress is a contribution to the 
biopharmaceutical sector and reinforces the imminent need for companies to 
adapt to this new reality. 
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1. Introduction 
The terms “advanced manufacturing”, “digitization” or “industry 4.0” (I4.0) have been 
widely cited in the general literature and are directly related to the future of manufacturing 
and maintaining industrial competitiveness. The world is facing a new industrial revolution 
that is happening at a faster pace than the previous ones. The central idea is the fusion or 
integration between the virtual and the real world trough elements that will allow a greater 
degree of automation and digitization of processes (Figure 1). The term I4.0 originated from 
a project integrated with the high-tech strategy of the German government, and aimed at the 
automation and digitization of the manufacturing industry (Daudt & Willcox, 2016). 
 
Fig. 1. Industry 4.0 – Fourth Industrial Revolution (Great Myanmar Institute, 2016). 
As the concepts of I4.0 are still at an early stage, any attempt to classify their elements 
becomes complex. However, there is consensus about fundamental elements that underlie the 
notion ofI4.0, CPS (Cyber-Physical Systems) and the IoT (Internet of Things). The 
technologies that allow the applicability of I4.0, defined as structuring elements, include 
automation, Machine to Machine Communication (M2M), Artificial intelligence (AI), 
BigData analytics, cloud computing, systems integration and cybersecurity. Finally, the 
complementary elements are those that are not mandatory, but increase the possibilities of 
application of I4.0, which include 3D printing, RFID tag, QR code, augmented reality and 
virtual reality, among others (Sacomano & Sátyro, 2018). 
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1.1. The  Biopharmaceutical Industry 4.0 
Currently, investments in technological innovation are increasingly migrating from 
pharmochemical chemicals to biological ones (large molecules produced in living cells). The 
technological platforms for their production involve the use of living, attenuated or 
inactivated organisms, whole or in subunits, genetically modified or not, for the production 
of vaccines or biopharmaceuticals. They require an extraordinary technological challenge, 
involving expensive and sophisticated activities that include cell culture processes, high 
performance purification systems, quality control with highly sensitive methodologies, 
among others (Silva & Caulliraux, 2016). 
2. Methodology 
The methodology proposed for this study includes the interview of professionals who work 
in managerial positions in biopharmaceutical industries or I4.0 specialists. In this context, 10 
semi-structured interviews were carried out with professionals from different countries 
between August 2019 and January 2020. The objective was to collect information and 
perceptions about I4.0 in the biopharmaceutical sector and the expected impacts.  
All respondents and the institutions in which they operate had their identities preserved for 
reasons of industrial secrecy. The interviews were conducted using the semi-structured 
method, where there is a confluence of previously prepared questions (related to trends, 
impacts and mapping of the phenomenon studied around the world) with others generated 
from the responses of the interviewees. The information collected was analyzed by 
qualitative analysis methods, such as content and narrative analysis.  
3. Results 
Most respondents perceive a strong need for biopharmaceutical companies to adapt, by 
implementing the elements the elements of I4.0 in their operations, especially at the risk of 
losing competitiveness. Some respondents believe in a moderate trend due to industry 
characteristics and peculiarities that include severe regulatory requirements and risks to 
people's safety. Factors like these can slow I4.0 applications in the industry.  
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Table 1. Interviewees in the Field - Biopharmaceutical Sector Managers and Experts at I4.0 
Interviewed Company 
Characteristics 
Company Position Interviewed Category 
A Portugal Private 
Pharmaceutical 
Industrial Director - 
Portugal 
Biopharmaceutical 
Manager 
B Portugal Private 
Pharmaceutical 
Digital Transformation 
Project Manager - 
Portugal 
Biopharmaceutical 
Manager 
C Transnational Private 
Bioharmaceutical 
Academic Management 
Program Manager - Spain 
Biopharmaceutical 
Manager 
D Brazilian Private 
Bioharmaceutical 
Production Director - 
Brazil 
Biopharmaceutical 
Manager 
E Transnational Private 
Bioharmaceutical 
IT Manager - Brazil Biopharmaceutical 
Manager 
F Digital Transformation 
in Production Lines 
Digital Latin America - 
Brazil 
Biopharmaceutical 
Manager 
G Artificial Intelligence 
(AI) Consulting and I4.0 
Head of Machine 
Learning and Innovation 
R&D - EUA 
I4.0 Specilist 
H Digital Transformation 
in Production Lines 
Director (CEO) - 
Portugal 
I4.0 Specilist 
I Academy 
Public University – 
Coimbra 
Full Professor of 
Robotics - Portugal 
I4.0 Specilist 
J Private Microconductor  
Company I4.0 - Portugal 
Company Owner and 
Director - Portugal 
I4.0 Specilist 
 
While explaining individual perceptions a diverse set of aspects come to debate. The 
efficiency gain in operations was the most scored amongst respondents, from the perspective 
of reducing waste, reducing operating costs and increasing productivity. These benefits are 
supported by the prospects of real-time quality controls, more detailed process data collection 
and analysis or predictive equipment maintenance. Quality-related gains, production 
customization, and reduced time to launch new products were also frequently scored (Figure 
3). The literature describes that the adoption of new I4.0-based technologies is expected to 
improve biopharmaceutical companies towards establishing more robust, flexible and faster 
manufacturing processes, reducing unplanned outages, fewer equipment defects, better 
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deadlines, and more agile quality management, analysis and decision making (Markarian, 
2018). In addition to the expectation of greater productivity, the interviewees reinforced that 
real-time monitoring allows the identification of characteristics that make it impossible, for 
example, to continue a batch, avoiding waste of working hours, energy consumption and raw 
materials. 
 
Figure 2. Main benefits identified by respondents of I4.0 in the production of biomedicines. 
As described in literature, products obtained in living systems are usually unstable and 
unpredictable (Silva & Caulliraux, 2016). Therefore, intense and rigorous monitoring in real 
time is essential. This minimizes the possibility of unwanted products and consequently 
increases productivity. In a cell fermentation or propagation process, for example, the more 
closely monitored the reaction medium containing living cells, the greater the possibility of 
obtaining the desired products. Compared to conventional strategy, the higher level of control 
and monitoring (based on complex algorithms) will allow analysis and predictive actions to 
avoid process or equipment failures (Romero-Torres et al., 2018). In this sector equipment is 
generally aseptic and often subjected to aggressive cleaning agents. Therefore, many of them 
have significantly high episodes of malfunctions. It is important to detect this predictively so 
that actions can be taken in advance. Most respondents, especially managers working in the 
sector, scored this benefit. 
Interesting also in this sector is the possibility of increasingly automated production 
processes, with machines interacting directly with other machines (M2M) without human 
intervention. In aseptic processes, the presence of any particles (man is the main source) can 
lead to episodes of batch contamination and damage to millionaires. In the era of I4.0, 
products are equipped with identifiers, such as QR bar codes or RFID tags, which after being 
read by the equipment are able to guide the correct sequence of operations through them 
(Sacomano & Sátyro, 2018) Some respondents antecipate gains in quality and efficiency with 
the reduction of failures linked to the human condition.  
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Intelligent processes are expected to be increasingly useful in the biopharmaceutical field. A 
temperature or pH sensor positioned at a specific point in a bioprocess, for example, can not 
only transmit the collected values to a computer or cellular exchange, but also compare them 
to programmed default values and, if necessary, output signals to actuators correct 
temperature or pH without any human intervention (Sacomano & Sátyro, 2018). The 
possibility of using intelligent aseptic robots can also be highly interesting in overly repetitive 
processes or involving physical, chemical or biological hazards (Keller et al., 2018). As 
reported in the interviews, there is the prospect of extraordinary gains in mitigating 
ergonomic risks, efficiency, productivity, among others. 
Respondents also frequently cited benefits related to digitization and paper replacement. The 
sensors collect process data and forward it to servers or computers in the cloud for storage 
and tracking. Punctuated benefits such as socio-environmental responsibility, reliability of 
data storage under GMP conditions, reduction of bureaucracy and quality are directly related 
to the theme. The direct connection between CPS, IoT, Big Data, AI and cloud computing 
will allow the analysis and crossing of this data in a more precise and profound way, resulting 
in several other benefits mentioned (efficiency, productivity, optimization of resources, 
among others). Research shows that approximately 70% of the data collected today in the 
biopharmaceutical industry is unused (Manzano & Langer, 2018).  
The possibility of more personalized medicines produced on more flexible production lines 
was also punctuated in the field interviews. This is an interesting perspective because it is 
common for certain biomedicines (therapeutic proteins, for example) to serve a small and 
targeted number of patients. Elements in I4.0 are expected to be able to offer leaner 
production processes that compensate for production on smaller scales and offer affordable 
market costs. Factories designed in modular structures, for example, allow greater flexibility 
and customization in the manufacture of products (Hammer, 2018). The range of single use 
systems or equipment is another recent challenge in the biopharmaceutical industry. A 
bioreactor, for example, requires significant manual efforts to connect all the necessary parts 
to the process. A system can be configured to require the operator to register the barcode on 
each disposable part to ensure proper component assembly and registration (Markarian, 
2018). Virtual or augmented reality tools can also help in this regard, avoiding errors, waste 
and increasing the security of the process. All of these benefits were raised by the 
interviewees. Another point cited by the interviewees, especially the experts, is the 
expectation that more products will be made available to consumers more quickly. Among 
other elements of I4.0 used for this purpose (Big Data, 3D Printing etc.), modern virtual 
simulators, for example, quickly manufacture and evaluate products under development, 
without the need for physical occupation of the factory. 
Regarding the main barriers and risks, opinions were quite varied. Reference goes to aspects 
commonly discussed in the literature, as the difficulty in breaking organizational patterns and 
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cultures, the stringent regulatory requirements of the biopharmaceutical sector, the lack of 
definition of strategic alignment for the implementation of the I4.0 elements, high investment 
and lack of qualified professionals. The interviewees also stressed that it is no use for 
companies to invest heavily in technological elements of I4.0 if they do not consider strongly 
the aspects mentioned. 
 
Figure 3. Main barriers identified by respondents in the adoption of I4.0 in the production of biomedicines. 
Factors such as low or old IT infrastructure, poor dissemination of I4.0 culture in society 
(customers, suppliers, regulatory agencies, etc.), lack of business maturity and difficulties in 
system integration were also cited. The integration between the different systems is extremely 
challenging point to I4.0. Efforts to standardize the systems are being made among 
manufacturers to reduce this problem (Romero-Torres et al., 2018). The fragility of 
information security systems was also addressed in the interviews. It is good practice to 
separate business data from GMP (Good Manufacturing Practice) production data using a 
kind of "industrial segregated zone" (Markarian, 2018). Keeping security levels current with 
the amount of data as a result of increasing connectivity between systems, equipment, and 
processes that communicate through IoT is highly challenging. The “social bubble” caused 
by automation and consequent unemployment was also pointed out as a growing concern. 
Some studies have been helpful in comparing I4.0's slower pace of insertion into the 
biopharmaceutical industry than in other areas, such as a Silicon Valley semiconductor 
company (Romero-Torres et al., 2017). As corroborated by the interviewees, this can be 
justified by some sector peculiarities. In addition to the regulatory issues inherent in products 
directly related to life, there is the complexity of biotechnology processes (reported especially 
by biopharmaceutical managers) and the absence of concrete cases in the literature (little 
exchange of experience). About the last, most of the documents were found in electronic 
journals specialized in the biopharmaceutical sector and not in the traditional scientific bases. 
Probably this fact stems from the scientific incipience of the subject.  
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Figure 4. The main technological elements of I4.0. 
The figure above summarizes the technological elements of I4.0 and some of the main 
benefits mentioned in the field interview. In the perception of the interviewees in general, it 
is essential that companies carefully align the organization's strategies and needs with the 
available technological elements. It is of utmost importance to carry out a prior assessment 
on the conditions of integration between systems, equipment and technologies.  
4. Conclusion 
Overall, field interviews reinforce not only the trend, but the need for biopharmaceutical 
companies to move into the I4.0 era, especially at the risk of losing competitiveness. The 
field results, quite diversified, confirmed the main impacts reported in the literature, in 
addition to bringing others. As for the benefits, efficiency was the main point raised, followed 
by gains in quality and increased productivity. Gains related to personalization, reduced 
ergonomic risks and reduced time to market were also scored. Regarding the main barriers, 
questions were raised that even contribute to a slower pace of implementation of I4.0 than in 
other sectors. Strict regulatory aspects, the need to break organizational cultures, the lack of 
qualified professionals, the lack of strategic alignment for implementation and high 
investment were frequently scored. Others, such as, the high complexity of biological 
processes and the threat of a "social bubble" due to the reduction in job availability caused 
by process automation were also addressed. The low number of scientific articles focused on 
the area still shows incipience and presents the opportunity for new publications, in addition 
to encouraging organizations to move into the I4.0 era. It is essential to deepen the exchange 
of experience and knowledge between producers (the entire logistics chain), regulatory 
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agents and society itself. As a limitation of the study, we can consider the low number of 
respondents and the consequent impossibility of statistical treatment to provide more 
consistent conclusions. The expectation is that a new study will be carried out with a more 
in-depth systematic review, the participation of more respondents and the identification of 
case by area companies that have already gone through the digitization process. 
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